Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New research from NDM’s Target Discovery Institute, the MRC Laboratory of Molecular Biology and University College London has shed light on a potential pathway for the spread of harmful tau protein in Alzheimer's disease. Their findings, published in Nature Neuroscience, focus on structures called extracellular vesicles and their role in transporting toxic tau fragments.

Elderly care

A hallmark of Alzheimer's and other dementias is the spreading and build-up of misfolded tau protein inside brain cells. Toxic tau proteins have been found within tiny lipid-enclosed structures called extracellular vesicles that actively ferry materials between cells. Vesicles containing tau might actually be spreading the bad protein to healthy cells, worsening the disease. It had been proposed that vesicles might be a way for brain cells to dispose of unwanted tau, but this had never been directly visualised.

The research team used deep proteomic profiling (Dr Darragh O'Brien and Prof Roman Fischer, Oxford Target Discovery Institute) to analyse the contents of extracellular vesicles from the brains of people diagnosed with Alzheimer's Disease. They discovered that secreted vesicles originating from the cell's waste disposal system contained toxic filamentous versions of tau proteins thought to be particularly damaging and difficult for cells to clear.

Using cryogenic electron microscopy, Dr Ryskeldi-Falcon and Tiana Behr determined that the structure of tau filaments within vesicles was similar, but not identical to the previously-reported tau structure in Alzheimer's Disease. The team discovered that tau in extracellular vesicles is in complex with an extra density that runs along the length of the filament, potentially offering clues into partner molecules that may encourage their toxic assembly.

Imaging of whole, intact extracellular vesicles indicated that the tau cargoes were attached, or tethered to the inner vesicle walls, hinting at a specific mechanism for tau packaging into vesicles.

This research provides critical insights into the formation and spread of toxic tau, paving the way for new therapies aimed at blocking tau transmission and potentially slowing or halting Alzheimer's progression. The identification of tau-carrying vesicles also offers a potential pathway for earlier diagnosis. Targeting the attachment of tau to these vesicles represents a promising strategy to disrupt the spread of harmful tau filaments.

Dr Steph Fowler's current research programme at the Oxford-GSK IMCM uses neuronal models of tauopathy to track toxic tau forms from their genesis to their secretion. Using multiomic tools and super-resolution microscopy, her team aims to uncover novel therapeutic targets to prevent or slow the spread of tauopathy.

Read the full article in Nature Neuroscience: https://www.nature.com/articles/s41593-024-01801-5

Similar stories

New insights into cellular pH regulators could inform research into neurological disease and cancer

High-resolution structures of two proteins that regulate acidity inside cells reveal how they interact with ions and membrane lipids, providing new insights into their roles in disease and potential avenues for drug discovery.

Building the world's evidence base to tackle drug-resistant tuberculosis

£10 million international research programme launches across India, Kazakhstan, Mozambique, South Africa and Vietnam.

A New Layer of Control for a Decades-Old Leukemia Drug

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led jointly by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug sensitivity and reveals that its role has nothing to do with its enzymatic activity.

Team ATLAS sets out strategy to investigate cancer avoidance as part of Cancer Grand Challenges

A new position paper from team ATLAS sets out plans to build a cancer antibody atlas to investigate why some people avoid cancer, while others develop disease.

Decades old puzzle solved as scientists uncover cause of inflammatory bowel disease

Scientists have identified the missing link between a long-known genetic signal in inflammatory bowel disease and a damaging immune response that switches off the body’s natural control of inflammation - opening the door to faster diagnosis and targeted treatment.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.